AZD3480 (TC-1734) FOR THE TREATMENT OF ADULT ADHD

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 注意力缺陷多动障碍（ADHD）是儿童期最常见的心理障碍之一。 虽然ADHD首次出现在儿童时期，但对于高达80%的儿童诊断的人来说，症状持续到青春期和成年期。 目前治疗ADHD的药物是精神兴奋剂（如利他林）。 这些药物并不对所有ADHD患者有效，有些人对这些药物有副作用。 研究表明，一种不同类型的药物，增加乙酰胆碱（大脑中自然产生的化学物质）的数量，也可以减轻ADHD的一些症状，并改善ADHD的一些认知缺陷。 然而，没有批准的胆碱能治疗ADHD。 TC-1734是一种作用于胆碱能系统的新药，在人类的初步研究中显示出认知益处。 这是一项初步研究，以确定TC 1734对ADHD成人症状和认知表现的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Attention Deficit/Hyperactivity Disorder (ADHD) is one of the most common childhood psychological disorders. While ADHD first appears in childhood the symptoms persist into adolescence and adulthood for up to 80% of people who are diagnosed as children. The current medications to treat ADHD are the psychostimulants (such as Ritalin). These medications are not effective for all people with ADHD and some people have side effects to these medications. Research has demonstrated that a different type of drug, ones that increase the amount of acetylcholine (a naturally occurring chemical in your brain) can also alleviate some of the symptoms of ADHD and also improve some of the cognitive deficits in ADHD. However there are no approved cholinergic treatments for ADHD. TC-1734 is a new drug which works on the cholinergic system and shows cognitive benefits in pilot studies in humans. This is a pilot study to determine the effects of TC1734 on the symptoms and cognitive performance in adults with ADHD.